Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments of $82.3M in Q2 FY2026
Q2 FY2026 short-term investments was $82.3M.
Context
- Short-term investments amounted to 64.1% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 112.08M USD
- Year-over-year change
- +189.7%
- 1-year CAGR
- +189.7%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.08M | +189.7% |
| FY2024 | 2024-12-31 | 38.69M | — |
Short-term Investments vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 64.1% of total assets for ATTO, versus a peer median of 13.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | Sep 2026 | $728.76M USD | +182.6% | — | 59.2% |
ALMSAlumis Inc. Common Stock | Jun 2026 | $438.59M USD | +31.1% | +48.2% | 78.2% |
EVMNEvommune, Inc. | Mar 2026 | $163.15M USD | +282.0% | — | 50.6% |
| Jun 2026 | $82.3M USD | — | — | 64.1% | |
| Mar 2026 | $76.76M USD | +2.4% | -25.7% | 38.6% | |
| Mar 2026 | $59.43M USD | -71.5% | +22.2% | 14.8% | |
| Mar 2026 | $37.99M USD | -84.3% | -41.7% | 11.5% | |
| Dec 2025 | $6M USD | -61.2% | -56.6% | 10.7% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding ATTO) | — | +2.4% | -25.7% | 13.2% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 30.63M | 40.19M |
| Short-term Investments | 38.69M | 112.08M |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 3.16M | 4.03M |
| Total Current Assets | 72.48M | 156.3M |
| Property, Plant & Equipment (Net) | 3.23M | 7.87M |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 607K | 404K |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 393K | 1.33M |
| Total Non-current Assets | 4.23M | 9.6M |
| Total Assets | 76.72M | 165.89M |
| Account Payables | 4.14M | 3.55M |
| Short-term Debt | 0 | 1.92M |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 450K |
| Other Current Liabilities | 1.52M | 1.98M |
| Total Current Liabilities | 7.72M | 11.01M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 6.87M | 755K |
| Total Non-current Liabilities | 6.87M | 4.1M |
| Total Liabilities | 14.59M | 15.1M |
| Common Stock | 1K | 1K |
| Retained Earnings | (50.38M) | (111.01M) |
| Accumulated OCI | 67K | 99K |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 62.13M | 150.79M |
| Total Debt | 0 | 5.26M |
| Net Debt | (30.63M) | (34.93M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.